Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Organon & Co Profile



Ticker SymbolOGN

Company nameOrganon & Co

IPO dateMay 14, 2021

CEOMorrissey (Joseph T)

Number of employees10000

Security typeOrdinary Share

Fiscal year-endMay 14

Address30 Hudson Street

CityJERSEY CITY

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryUnited States of America

Postal code07302

Phone15514306000

Websitehttps://www.organon.com/

Ticker SymbolOGN

IPO dateMay 14, 2021

CEOMorrissey (Joseph T)

Company Executives of Organon & Co



Name

Name/Position

Position

Shareholding

Change

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

101.67K

+4.83%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

101.67K

+4.83%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

101.67K

+4.83%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

92.70K

+0.06%

Name

Name/Position

Position

Shareholding

Change

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

FAQs

Who are the top five shareholders of Organon & Co?



The top five shareholders of Organon & Co are: Mr. Matthew M. (Matt) Walsh

How many institutions hold shares of Organon & Co (OGN)?



As of 2026Q1, 1398 institutions hold shares of Organon & Co, with a combined market value of approximately 239.27M, accounting for 91.12% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3985201.00.

What is the biggest source of revenue for Organon & Co?



In 2026Q1, the Women’s Health business generated the highest revenue for Organon & Co, amounting to 419.00M and accounting for 26.89% of total revenue.